- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Warsaw Today
By the People, for the People
OrthoPediatrics Reports Strong Q4 2025 Results
Company posts first quarter of positive free cash flow and outlines multi-year product launch cycle
Published on Feb. 26, 2026
Got story updates? Submit your updates here. ›
OrthoPediatrics (NASDAQ:KIDS) reported fourth-quarter 2025 results that management said capped a strong year of growth and improving profitability, highlighted by the company's first quarter of positive free cash flow in its history. Executives also outlined a multi-year cycle of product launches they believe will support continued market share gains across pediatric orthopedics and expand the company's presence in adjacent pediatric subspecialties.
Why it matters
OrthoPediatrics is a leading provider of specialized orthopedic solutions for children, and its strong Q4 2025 performance and pipeline of new product launches signal the company's continued momentum in the pediatric medical device market. The achievement of positive free cash flow is a significant milestone that demonstrates the company's improving financial position and ability to fund future growth initiatives.
The details
In the fourth quarter, OrthoPediatrics reported 17% revenue growth, with U.S. revenue up 13% and international revenue rising 33%. The company also generated $10 million in free cash flow, its first quarter of positive free cash flow. Gross profit margin improved to 73% from 68% a year earlier, and adjusted EBITDA increased 59% to $4.8 million. The company's Trauma and Deformity and Scoliosis segments both saw double-digit growth, while the OPSB specialty bracing business continued to be a 'strategic growth catalyst.' OrthoPediatrics also made progress on EU MDR approvals, which the company expects will support growth in Europe in 2026.
- In the fourth quarter of 2025, OrthoPediatrics supported the treatment of more than 37,500 children, bringing its total impact to about 1.3 million children helped.
- OrthoPediatrics reported fourth-quarter 2025 worldwide revenue of $61.6 million, up 17% from the prior-year period.
The players
OrthoPediatrics
An Indiana-based medical device company dedicated exclusively to providing orthopedic solutions for children.
David Bailey
Chief Executive Officer of OrthoPediatrics.
Fred Hite
Chief Operating and Financial Officer of OrthoPediatrics.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee (Instagram)
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.
